1. Background
2. Objectives
3. Methods
3.1. Imaging Modalities
3.2. Statistical Analysis
4. Results
| Variables | Values |
|---|---|
| Gender | |
| Female | 21 (35) |
| Male | 39 (65) |
| Age (y) | 4.92 ± 4.01 |
| Comorbidities | 18 (30) |
| Neurologic disease | 4 (22.2) |
| Pulmonary disease | 2 (11.1) |
| Malignancy | 6 (33.3) |
| Digestive diseases | 2 (11.1) |
| Other | 4 (22.2) |
| Symptoms | |
| Fever | 52 (86.7) |
| Cough | 40 (66.7) |
| Dyspnea | 21 (35.0) |
| Laboratory results | |
| WBC | 8.85 ± 5.19 |
| RBC | 4.76 ± 5.01 |
| Lymphocyte percentage | 34.54 ± 16.65 |
| Neutrophil percentage | 58.91 ± 18.25 |
| Hemoglobin | 11.68 ± 1.86 |
| Platelets | 342.81 ± 171.36 |
| C-reactive protein | 22.52 ± 14.21 |
| ESR | 30.66 ± 19.96 |
| AST | 61.53 ± 144.95 |
| LDH | 621.21 ± 231.25 |
| SARS-CoV-2 (RT-PCR) test | 59 (98.3) |
| Positive | 50 (84.7) |
| Negative | 9 (15.3) |
Abbreviations: WBC, white blood cell count; RBC, red blood cell count; ESR, erythrocyte sedimentation rate; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; RT-PCR, reverse transcription-polymerase chain reaction.
a Values are expressed as No. (%) or mean ± SD.
| Variables | Values |
|---|---|
| CT findings | 29 (48.3) |
| Lesion characteristics | 28 |
| Consolidation | 13 (46.4) |
| Ground-glass opacity | 3 (10.7) |
| Mixed pattern | 12 (42.9) |
| Nodular | 5 (17.9) |
| Round or well-defined opacity | 2 (7.1) |
| Halo sign | 1 (3.6) |
| Type of ground-glass opacity | 9 |
| Pure ground-glass opacity | 7 (77.8) |
| Crazy paving | 2 (22.2) |
| Type of consolidation | 18 |
| Non lobular | 14 (77.8) |
| Lobular | 4 (22.2) |
| Pleural effusion | 3 (10.3) |
| Mild | 2 (66.7) |
| Severe | 1 (33.3) |
| Lymphadenopathy | 4 (13.8) |
| COVID-19 imaging classification | 28 |
| Typical appearance | 12 (42.9) |
| Indeterminate appearance | 15 (53.6) |
| Atypical appearance | 1 (3.6) |
| Negative for pneumonia | 0 |
| Average of CT severity score | 5.82 ± 3.82 |
| LUS findings | 59 (98.3) |
| Pleural effusion | 2 (3.4) |
| Average of LUS score | 6.28 ± 4.49 |
| CXR findings | 35 (58.3) |
| Normal | 19 (54.3) |
| Increased bronchovesicular marking | 9 (25.7) |
| Consolidation | 4 (11.4) |
| Ground-glass opacity | 2 (5.7) |
| Pleural effusion | 1 (2.9) |
Abbreviations: LUS, lung ultrasound; CT, computed tomography; CXR, chest X-ray.
a Values are expressed as No. (%) or mean ± SD.
| Abnormal Imaging | Definite (PCR Positive); N = 50 | Probable (PCR Negative); N = 10 |
|---|---|---|
| LUS (38) | 31 (62) | 8 (80) |
| Chest CT (29) | 19 (38) | 10 (100) |
| CXR (16) | 15 (30) | 1 (10) |
Abbreviations: PCR, polymerase chain reaction; LUS, lung ultrasound; CT, computed tomography; CXR, chest X-ray.
a Values are expressed as No. (%).